Biolinq develops a wearable biosensor platform that is capable of measuring blood level information.
Biolinq develops a wearable biosensor platform that is capable of measuring blood level information.
Monitoring Equipment📍 San Diego, CAFounded 2012
Current Valuation
$395M
as of 2025-Q2
PRIVATE
QL Price
$395M
0% vs last round
QuantLogix's current estimate for Biolinq, published 2026-09-27 — in line with the last disclosed round of $395M (2025-Q2).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$395M
2025-Q2
weight 0.42
How this price has held up
No round has priced for Biolinq since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Biolinq, 2026-09-27 (404fd7f01c4e6dc9).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Biolinq going public?
No. Biolinq is private and has not filed to go public. There is no S-1 on file.
What is Biolinq's valuation in 2026?
Biolinq is valued at $395M as of 2025-Q2, set by its Series C ($100M, Apr 2025). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Biolinq filed an S-1?
No public S-1 is on file for Biolinq.
How much has Biolinq raised?
Biolinq has raised $312.79M in total, most recently a Series C of $100M in Apr 2025.
Is Biolinq publicly traded — can you buy Biolinq stock?
No. Biolinq is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Biolinq on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2012
HQ
San Diego, CA
Employees
111
Total Raised
$312.79M
Last Round
Series C — $100M (Apr 2025)
IPO Status
private
Fundraising Status
Series C · $100M · 1y 5mo ago
privateTotal raised $312.79M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$100M
Apr 2025
—
$395M
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
2
0 active · 0 recruiting
Focus areas
Diabetes
Diabetes Mellitus
Latest trial start
2024-09-10
Name-verified against lead sponsor "Biolinq Inc." on ClinicalTrials.gov as of 2026-09-19. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
● First snapshot
trend accrues with monthly sweeps
Open roles
14
via careers page
Product-build share
79%
engineering, research, product, design
Trajectory
steady
heavy product build — 79% of open roles are product-building functions (engineering/research/product) — 4 of 14 open roles are engineering.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Manufacturing SupervisorClinical Project ManagerResearch Associate I (R&D)Research Associate II (Advanced Sensor Technologies)Research Associate I (Advanced Sensor Technology)Senior Software Engineer/ iOS
Counted from Biolinq's live job board as of 2026-09-14; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
BiotechnologyHealth CareMedical Device
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q2. Refreshed quarterly.